8-K: Humana Reports Solid First Quarter 2025 Results, Reaffirms Adjusted EPS Guidance

Humana reported first quarter 2025 financial results, with adjusted EPS ahead of expectations and reaffirmed its full-year adjusted EPS guidance of approximately $16.25.

Summary

• Humana reported a solid start to 2025, with the first quarter Insurance segment benefit ratio at 87.4%.
• The company's first quarter Adjusted EPS was ahead of expectations, driven by a shift in the timing of administrative expenses and outperformance in CenterWell.
• Humana reaffirmed its 2025 guidance, including an Adjusted EPS outlook of approximately $16.25 and an Insurance segment benefit ratio guidance range of 90.1% to 90.5%.
• The company remains committed to achieving an individual Medicare Advantage (MA) pretax margin of at least 3% over time.
• Humana anticipates a few hundred million dollars of incremental investments in 2025 to improve member and patient outcomes and support operational excellence.
• The company expanded its CenterWell platform, with CenterWell Primary Care growing by 27,300 patients, or 7%, since December 31, 2024.
• CenterWell Pharmacy was selected as the fulfillment pharmacy for NovoCare Pharmacy's weight loss medication for cash pay customers.
• Humana is strategically expanding its Medicaid platform, with Illinois intending to award Humana their new Fully Integrated Dual Eligible (FIDE) Special Needs Plan (SNP) program, expected to start in 2026.
• The 2026 final MA rate notice better reflects the medical cost trend environment, which should enable greater stability within the industry.
• Humana's individual Medicare Advantage (MA) 1Q25 year-to-date (YTD) membership decline of approximately 446,000 is in line with expectations.
• The company continues to anticipate a full-year (FY) 2025 decline of approximately 550,000 members, largely driven by the decision to exit certain unprofitable plans and counties.
• Humana expects its premium yield to be in the high single digits for the full year, driven by an increased direct subsidy due to the Inflation Reduction Act (IRA).
• Group MA is performing as anticipated to date, with revenue and medical cost trends developing in line with expectations.
• Humana continues to anticipate modest improvement in its Medicaid margin in 2025 as additional states progress through the J curve and rates are updated to reflect the acuity level of members and trend experience related to the Public Health Emergency (PHE) unwind.
• CenterWell outperformed expectations in the quarter, inclusive of timing-related items.
• Humana is operating 329 centers as of March 31, 2025, representing growth of 30 centers, or 10%, year over year, while representing a reduction of 15 centers, or 4%, from December 31, 2024.
• Within CenterWell Home Health, 1Q25 same-store admissions grew approximately 1% year over year.
• Humana expects second quarter earnings to be approximately 35% of expected full year 2025 Adjusted earnings.
• The company raised $1.5 billion in the debt markets during the first quarter, which covers its maturities through the end of 2026.
• Debt to capitalization as of March 31, 2025, is 42.8%, and Humana continues to target a debt to capitalization ratio of approximately 40% over the long term.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While Humana reaffirmed its adjusted EPS guidance and reported positive developments in CenterWell and Medicaid, the decline in Medicare Advantage membership and the revision of GAAP EPS guidance temper the overall outlook.

Positives

• Humana's first quarter Adjusted EPS was ahead of expectations.
• The company reaffirmed its 2025 Adjusted EPS guidance.
• CenterWell Primary Care is experiencing significant patient growth, particularly in de novo centers.
• Humana is strategically expanding its Medicaid platform with the Illinois FIDE SNP program award.
• Humana's premium yield is expected to be in the high single digits for the full year, driven by the Inflation Reduction Act (IRA).
• CenterWell outperformed expectations in the quarter.

Negatives

• Humana expects a decline of approximately 550,000 members in individual Medicare Advantage due to exiting unprofitable plans.
• Group MA had margin pressure in 2024 that, as expected, continued into 2025 due to multi-year pricing cycles.
• Humana revised its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $14.68' from 'approximately $15.88'.

Risks

• The company's profitability could be materially adversely affected if Humana does not design and price its products properly and competitively.
• If Humana fails to effectively implement its operational and strategic initiatives, the company's business may be materially adversely affected.
• The number of Humana's Medicare Advantage plans rated 4-star or higher will significantly decline in 2025.
• Changes to the risk-adjustment model utilized by CMS could have a material adverse effect on the company's operating results, financial position and cash flows.
• Humana's business activities are subject to substantial government regulation, and changes in laws or regulations could increase the company's cost of doing business.
• Humana's failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company's results of operations, financial position, and cash flows.

Future Outlook

Humana reaffirmed its full-year 2025 adjusted EPS guidance of approximately $16.25 and expects to achieve an individual Medicare Advantage pretax margin of at least 3% over time. The company anticipates continued growth in its CenterWell and Medicaid businesses.

Management Comments

• Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid, said Humana President and CEO Jim Rechtin.
• We are confident in the growth outlook for value-based care and Medicare Advantage, which will allow us to provide more quality care to a broader group of patients and members.

Industry Context

The report highlights the increasing importance of value-based care and the growing role of Medicare Advantage in providing affordable healthcare to seniors. The company's expansion in CenterWell and Medicaid reflects a broader industry trend towards integrated care delivery models.

Comparison to Industry Standards

• Humana's focus on Medicare Advantage aligns with industry trends, as companies like UnitedHealth Group and CVS Health (Aetna) also have significant presence in this market.
• The expansion of CenterWell is comparable to other healthcare providers investing in primary care and home health services, such as Optum (UnitedHealth Group) and Walgreens.
• The company's efforts to improve Star Ratings are crucial, as these ratings directly impact reimbursement rates from CMS, similar to other major players in the Medicare Advantage market.

Stakeholder Impact

• Shareholders: The reaffirmation of adjusted EPS guidance and commitment to margin expansion are positive for shareholders.
• Members: Investments in improving member outcomes and operational excellence are expected to benefit members.
• Patients: Expansion of CenterWell Primary Care and Home Health services will provide more access to care for patients.
• Employees: Efforts to increase efficiency and improve operational performance may impact employees.

Next Steps

• Humana will host a live question-and-answer session for analysts to discuss the financial results.
• The company will continue to work with the Administration and policymakers in Congress to strengthen the MA program.
• Humana will share more on its midand longer-term outlook at its 2025 Investor Conference on June 16, 2025.
• Humana will re-evaluate its capital deployment plans throughout the year.

Key Dates

Keywords

Humana, Medicare Advantage, CenterWell, Medicaid, EPS, Financial Results, Insurance, Guidance